Key result
Essential thrombocythemia patients exhibited a significantly lower 24-hour antiplatelet effect of aspirin compared to coronary artery disease patients, with a median difference in thromboxane B2 delta levels of 22.5 ng/mL (p<0.0001).
Why the study?
Because essential thrombocythemia is a platelet disorder, platelets may be more important for thromboembolic risk in ET than in CAD, prompting investigation into whether aspirin's antiplatelet effect and platelet turnover differ between these groups.
Does the antiplatelet effect of aspirin differ between patients with essential thrombocythemia and those with coronary artery disease?
Cohort (n=96)
No
Does the antiplatelet effect of aspirin differ between patients with essential thrombocythemia and those with coronary artery disease?
Patients with essential thrombocythemia exhibit a significantly lower antiplatelet effect of aspirin compared to patients with coronary artery disease, likely driven by increased platelet turnover.
Answers are grounded in this paper and cite their sources.
May warrant tailored aspirin regimens in essential thrombocythemia; hypothesis-generating and requires prospective validation before practice change.
Background Patients with essential thrombocythemia (ET) and coronary artery disease (CAD) have increased risk of thromboembolic complications. In addition, a reduced antiplatelet effect of aspirin has been demonstrated in both patient groups. As ET is a platelet disorder, platelets may be more important for the thromboembolic risk in ET than in CAD. We aimed to investigate the antiplatelet effect of aspirin and platelet turnover in ET versus CAD patients. Methods We included 48 ET patients and an age-matched group of 48 CAD patients. The effect of aspirin was evaluated by thromboxane B2 (TXB2) levels and platelet aggregation. Platelet turnover was assessed by immature platelet count (IPC) and immature platelet fraction (IPF). Results ET patients had reduced effect of aspirin compared with CAD patients, demonstrated by significantly higher TXB2 levels (median of differences = 22.3 ng/mL, p < 0.0001) and platelet aggregation (median of differences = 131.0 AU*min, p = 0.0003). Furthermore, ET patients had significantly higher IPC (p < 0.0001) and IPF (p = 0.0004) than CAD patients. Conclusion ET patients have lower 24-hour antiplatelet effect of aspirin than CAD patients. This may be explained by an increased platelet production and turnover counteracting the antiplatelet effect of aspirin. These findings strengthen the rationale for exploring novel antiplatelet regimens in ET patients to reduce the risk of cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Pedersen et al. (2021) conducted a cohort in Essential Thrombocythemia and Coronary Artery Disease (n=96). Essential thrombocythemia vs. Coronary artery disease was evaluated on Difference in delta values (value 1 hour after aspirin intake minus the value 24 hours after aspirin intake) of thromboxane B2 (TXB2) levels (Median difference 22.5 ng/mL, p=<0.0001). Essential thrombocythemia patients exhibited a significantly lower 24-hour antiplatelet effect of aspirin compared to coronary artery disease patients, with a median difference in thromboxane B2 delta levels of 22.5 ng/mL (p<0.0001).
Synapse has enriched 10 related papers. Consider them for comparative context: